Enoxaparin sodium

Drug Profile

Enoxaparin sodium

Alternative Names: Clexane; Decipar; Enoxaparin; Enoxaparin Pen; Klexane; Levenox; Lovenox; PK 10169; PRY 005; RP 54563; RPY 005

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pharmuka
  • Developer G.L. Pharma; Italfarmaco; Sanofi
  • Class Antithrombotics; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis; Embolism; Myocardial infarction; Thromboembolism; Thrombosis; Unstable angina pectoris
  • Phase III Small cell lung cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Nov 2014 Enoxaparin sodium is still in a phase III trial for Small cell lung cancer in Sweden
  • 23 Jul 2010 First Generic equivalent approved and launched in USA for Thromboembolism ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top